Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Our popular solutions

Key benefits:

Direct access to your target Pharma audience
A cohesive marketing campaign
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Citeline, Biomedtracker, Pharma Consulting, Datamonitor Heal...

COVID-19 24 hour webinar recordings

Catch up on any missed COVID-19 24 hour webinar sessions

Topic Cardiovascular Coronavirus

Full video
Scrip

Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

View article
Citeline, Datamonitor Healthcare

COVID-19 24-hour web event: Lessons learned and a path forward

This web event has now ended. You will be able to watch all sessions on demand soon. Register your interest now to receive an update when all sessions are available to view.

Topic Coronavirus

View interactive data
Pink Sheet

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.

Topic Coronavirus Clinical Trials

View article
Generics Bulletin

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topic Coronavirus Distribution

View article
Generics Bulletin

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Topic Coronavirus

View article
Generics Bulletin

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Topic Coronavirus Intellectual Property Policy & Regulation

View article
Generics Bulletin

Remdesivir Licensing Agreements for Generics Companies

Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

Topic Drug Development Landscape

Single report
Awareness, Thought leadership, Scrip

Scrip Asia 100: Sponsorship Opportunities

The annual “Scrip Asia 100”, the highly anticipated financial performance ranking of pharma companies headquartered in the APAC region, is coming soon. Don’t miss your opportunity to position yourself as a leader in APAC pharma with a sponsorship in this indispensable publication.

Topic Company Analysis Market Intelligence Outlook

View article
HBW Insight

Italy's Supplements Market Gets Big Boost From COVID After Solid 2019

Coronavirus pandemic drove up sales of vitamin C supplements and other immunity boosters in Italy in the opening three months of the year.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

No Evidence That Vitamin D Prevents Or Treats COVID-19

UK's NICE reviews whether Vitamin D can prevent or treat COVID-19, finds evidence wanting.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

Nurofen Ad Pulled In NZ For Irresponsible Message During COVID Pandemic

Reckitt Benckiser's TV ad for Nurofen in New Zealand drew numerous complaints for being "socially irresponsible" during the COVID-19 pandemic.

Topic Coronavirus Advertising, Marketing & Sales

View article
HBW Insight

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

Assertions that no convincing evidence supports that probiotics available in the US treat symptoms of diarrhea, irritable bowel syndrome or allergies look at the category as a whole and not individual strains shown to help with specific conditions, say consumer health industry groups.

Topic Coronavirus Dietary Supplements Research & Development

View article
Pink Sheet

UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials

The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.

Topic Coronavirus Clinical Trials Vaccines

View article